OX40 and CD40 Agonists for the Treatment of Lung Cancer

Verma, N Thapa, K Kanojia, N Sood, P Kumar, J Thakur, N Dua, K

Permalink

Closed Access

	Filename	Description	Size
	978-981-99-7141-1_10.pdf	Published version	690.08 kB		View/Open

Copyright Clearance Process

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Verma, N
dc.contributor.author	Thapa, K
dc.contributor.author	Kanojia, N
dc.contributor.author	Sood, P
dc.contributor.author	Kumar, J
dc.contributor.author	Thakur, N
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2024-10-23T02:22:11Z
dc.date.available	2024-10-23T02:22:11Z
dc.date.issued	2024
dc.identifier.citation	Immunotherapy Against Lung Cancer, 2024, pp. 181-199
dc.identifier.isbn	9789819971404
dc.identifier.uri	http://hdl.handle.net/10453/181544
dc.language	en
dc.publisher	Springer Nature
dc.relation.ispartof	Immunotherapy Against Lung Cancer
dc.relation.isbasedon	10.1007/978-981-99-7141-1_10
dc.rights	info:eu-repo/semantics/closedAccess
dc.title	OX40 and CD40 Agonists for the Treatment of Lung Cancer
dc.type	Chapter
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)/Associate Member
pubs.organisational-group	University of Technology Sydney/UTS Groups/Australian Research Consortium in Complementary and Integrative Medicine (ARCCIM)
utslib.copyright.status	closed_access	*
dc.date.updated	2024-10-23T02:22:09Z
pubs.publication-status	Published

Please use this identifier to cite or link to this item: